The resolutions and decisions database offers for full text search and sorting:
| Arabic | Chinese | English | French | Russian |
Report of the Commission on Narcotic Drugs on its reconvened sixty-sixth session
Report of the Commission on Narcotic Drugs on its sixty-seventh session and provisional agenda for its sixty-eight session
Report of the International Narcotics Control Board
Promoting recovery and related support services for people with drug use disorders
Promoting awareness-raising, education, training and data collection as part of a comprehensive approach to ensuring access to and the availability of controlled substances for medical and scientific purposes, including for the treatment of children, and ensuring their rational use
Celebrating the tenth anniversary of the United Nations Guiding Principles on Alternative Development: effective implementation and the way forward
Preventing and responding to drug overdose through prevention, treatment, care and recovery measures, as well as other public health interventions, to address the harms associated with illicit drug use as part of a balanced, comprehensive, scientific evidence-based approach
Inclusion of butonitazene in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of 3-chloromethcathinone (3-CMC) in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of dipentylone in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 2-fluorodeschloroketamine in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of bromazolam in Schedule IV of the Convention on Psychotropic Substances of 1971
Inclusion of 4-piperidone in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of 1-boc-4-piperidone in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of P-2-P methyl glycidic acid (“BMK glycidic acid”) (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the methyl ester of P-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the ethyl ester of P-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the propyl ester of P-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the isopropyl ester of P-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the butyl ester of P-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the isobutyl ester of P-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the sec-butyl ester of P-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the tert-butyl ester of P-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl esters of P-2-P methyl glycidic acid in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 in the form of a footnote to P-2-P methyl glycidic acid
Inclusion of the ethyl ester of 3,4-MDP-2-P methyl glycidic acid (“PMK ethyl glycidate”) (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the propyl ester of 3,4-MDP-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the isopropyl ester of 3,4-MDP-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the butyl ester of 3,4-MDP-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the isobutyl ester of 3,4-MDP-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the sec-butyl ester of 3,4-MDP-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the tert-butyl ester of 3,4-MDP-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of the ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl esters of 3,4-MDP-2-P methyl glycidic acid (all stereoisomers) in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 in the form of a footnote to 3,4-MDP-2-P methyl glycidic acid
| Arabic | Chinese | English | French | Russian | Spanish |
Enhancing Action at National, Regional, and International Levels to Address the Global Public Health and Security Challenges Posed by Synthetic Drugs
Report of the Commission on Narcotic Drugs on its sixty-sixth session and provisional agenda for its sixty-seventh session
Report of the International Narcotics Control Board
Preparations for the midterm review to be held during the sixty-seventh session of the Commission on Narcotic Drugs, in 2024
Safe handling and disposal of synthetic drugs, their precursors and other chemicals used in the illicit manufacture of drugs
Strengthening information-sharing to increase scientific evidence-based support for international scheduling and the effective implementation of international scheduling decisions
Promoting alternative development as a development-oriented drug control strategy that is sustainable and inclusive
Inclusion of 2-methyl-AP-237 in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of etazene in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of etonitazepyne in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of protonitazene in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of ADB-BUTINACA in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of alpha-PiHP in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 3-methylmethcathinonein Schedule II of the Convention on Psychotropic Substances of 1971
| Arabic | Chinese | English | French | Russian | Spanish |
International cooperation to address and counter the world drug problem
Improving the governance and financial situation of the United Nations Office on Drugs and Crime: extension of the mandate of the standing open-ended intergovernmental working group on improving the governance and financial situation of the United Nations
Report of the Commission on Narcotic Drugs on its reconvened sixty-fourth session
Report of the Commission on Narcotic Drugs on its sixty-fifth session and provisional agenda for its sixty-sixth session
Promoting alternative development as a development-oriented drug control strategy, taking into account measures to protect the environment
Strengthening international cooperation to address the links between illicit drug trafficking and illicit firearms trafficking
Intensifying efforts to address the diversion of non-scheduled chemicals frequently used in the illicit manufacture of drugs and the proliferation of designer precursors
Promoting comprehensive and scientific evidence-based early prevention
Inclusion of brorphine in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of metonitazene in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of eutylone in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 4-AP in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of 1-boc-4-AP in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of norfentanyl in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
| Arabic | Chinese | English | French | Russian | Spanish |
International cooperation to address and counter the world drug problem
Report of the Commission on Narcotic Drugs on its reconvened sixty-third session
Report of the Commission on Narcotic Drugs on its sixty-fourth session and provisional agenda of its sixty-fifth session
Statement of the Commission on Narcotic Drugs on the impact of the coronavirus disease (COVID-19) pandemic on the implementation of Member States’ joint commitments to address and counter all aspects of the world drug problem
Promoting alternative development as a development-oriented drug control strategy, including in the context of the coronavirus disease (COVID-19) pandemic and its consequences
Promoting scientific evidence-based, quality, affordable and comprehensive drug prevention, treatment, sustained recovery and related support services
Improving data collection on, and responses to, the harmful effects of the non-medical use of pharmaceuticals containing narcotic drugs, psychotropic substances or new psychoactive substances
Facilitating access to comprehensive, scientific evidence-based drug demand reduction services and related measures, including for people impacted by social marginalization
Inclusion of isotonitazene in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of CUMYL-PEGACLONE in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of MDMB-4en-PINACA in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 3-methoxyphencyclidine in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of diphenidine in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of clonazolam in Schedule IV of the Convention on Psychotropic Substances of 1971
Inclusion of diclazepam in Schedule IV of the Convention on Psychotropic Substances of 1971
Inclusion of flubromazolam in Schedule IV of the Convention on Psychotropic Substances of 1971
| Arabic | Chinese | English | French | Russian | Spanish |
International cooperation to address and counter the world drug problem
Report of the Commission on Narcotic Drugs on its reconvened sixty-second session
Report of the Commission on Narcotic Drugs on its sixty-third session and provisional agenda for its sixty-fourth session
Report of the International Narcotic Control Board
Promoting efforts by Member States to address and counter the world drug problem, in particular supply reduction-related measures, through effective partnerships with private sector entities
Promoting and improving the collection and analysis of reliable and comparable data to strengthen balanced, integrated, comprehensive, multidisciplinary and scientific evidence-based responses to the world drug problem
Promoting awareness-raising, education and training as part of a comprehensive approach to ensuring access to and the availability of internationally controlled substances for medical and scientific purposes and improving their rational use
Promoting the involvement of youth in drug prevention efforts
Promoting alternative development as a development-oriented drug control strategy
Inclusion of methyl alpha-phenylacetoacetate (MAPA), including its optical isomers, in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of crotonylfentanyl in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of valerylfentanyl in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of DOC in Schedule I of the of the Convention on Psychotropic Substances of 1971
Inclusion of AB-FUBINACA in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 5F-AMB-PINACA (5F-AMB, 5F-MMB-PINACA) in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 5F-MDMB-PICA (5F-MDMB-2201) in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 4F-MDMB-BINACA in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 4-CMC (4-chloromethcathinone, clephedrone) in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of N-ethylhexedrone in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of alpha-PHP in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of flualprazolam in Schedule IV of the Convention on Psychotropic Substances of 1971
Inclusion of etizolam in Schedule IV of the Convention on Psychotropic Substances of 1971
Changes in the scope of control of substances: proposed scheduling recommendations by the World Health Organization on cannabis and cannabis-related substances
Improved and streamlined annual report questionnaire
